ClinicalTrials.gg
CompletedNCT05532722Updated May 6, 2026

ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

A Phase 1/2 interventional study of ABC008 in T-cell Large Granular Lymphocytic Leukemia, sponsored by Abcuro, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Abcuro, Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 113 studies in Leukemia, Large Granular Lymphocytic with a site in United States — 7 open to participants now, 12 under way, none of them phase 3. Leukemia, Large Granular Lymphocytic · United States.

Enrollment
58th of 86
21 · median 30
Started
2022
with 3 others
Phase 1/2
11 of 113
1 open now
Registered
111th of 113
by date

Among the 113 studies in Leukemia, Large Granular Lymphocytic with a site in United States, this one is the 58th largest by enrollment of the 86 interventional ones that give a count, is one of 4 that started in 2022, is one of 11 in phase 1/2, and was the 111th registered.

Leukemia, Large Granular Lymphocytic

144 studies on the registry are indexed under Leukemia, Large Granular Lymphocytic; 19 are open to participants now.

Browse Leukemia, Large Granular Lymphocytic studies →

Open to participants now

7 of the 113 studies in Leukemia, Large Granular Lymphocytic with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Leukemia, Large Granular Lymphocytic studies recruiting now, 13 (76%) set no upper age limit and 3 (18%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in Leukemia, Large Granular Lymphocytic with a site in United States, or all of them as a file.
02

Study summary

An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

03

Conditions studied

  • T-cell Large Granular Lymphocytic Leukemia

Keywords

  • T-cell Large Granular Lymphocytic Leukemia
  • T-LGLL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is at least 18 years of age.
  • Has (BMI) ≤35 kg/m2.
  • Has a documented diagnosis of T LGLL.
  • Has any 1 or more of the following at Screening:

    • (ANC) \<0.5 x 109/L
    • ANC ≥0.5 x 109/L and \<1.0 x 109/L associated with recurrent infection (≥2 or more infections requiring antimicrobial therapy within the previous 12 months)
    • (Hgb) \<8 g/dL or packed red blood cell transfusion frequency ≥1 time in the 4 weeks immediately prior to Screening
    • Hgb ≥8 g/dL and \<10 g/dL accompanied by documented symptoms of anemia, e.g., fatigue, weakness, pale or yellowish skin, irregular heartbeat, shortness of breath, dizziness, or lightheadedness.
  • Has adequate hepatic and renal function at Screening, as indicated by:

    • Serum (ALT) and aspartate aminotransferase (AST); \<2.5x the (ULN)
    • Total ≤1.5 ULN; subjects with Gilbert syndrome must have a total bilirubin \<3.0x ULN with direct bilirubin \<1.0x ULN at time of Screening
    • Estimated (eGFR) ≥45 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) equation corrected for the body surface area of the subject calculated by the Mosteller equation and divided by 1.73
  • Agrees to adhere to the current Centers for Disease Control advice regarding minimizing exposure to severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) from the first Screening Visit until the End of Study (EOS)/Early Termination Visit (ETV).

Exclusion criteria

Exclusion Criteria:

  • Has reactive large granular lymphocytosis.
  • Has active anemia secondary to confirmed etiologies other than T-LGLL, including known vitamin or mineral deficiency, gastrointestinal bleeding, or genetic disorder; or has active neutropenia secondary to known vitamin or mineral deficiencies or genetic disorder.
  • Has a count ≤20 x 109/L or other clinically significantly abnormal laboratory results not related to the underlying condition in the Investigator's or Sponsor's opinion at Screening.
  • Has known to any component of the formulation of ABC008, or history of anaphylaxis to any prior mAb therapy.
  • Has any other or autoinflammatory disease other than RA, inclusion body myositis (IBM), secondary Sjogren's syndrome (SS), or thyroid disease.
  • Has another myelo /lympho proliferative disorder or (other than monoclonal gammopathy of unknown significance [MGUS] not requiring treatment) within the past 5 years prior to Screening except completely resected nonmelanoma skin cancer, curatively treated localized prostate cancer, and completely resected carcinoma in situ at any site.
  • Has a current diagnosis of active tuberculosis (TB)
  • Has a history of herpes zoster infection that was disseminated, required hospitalization, or IV antiviral therapy in the 24 weeks prior to Day 1.
  • Active, chronic, or past history of virus or virus (HCV) infection (hepatitis B core antibody or surface antigen positive, or HCV antibody positive with reflex HCV ribonucleic acid [RNA] positive at Screening; individuals who have received curative therapy for HCV are permitted if therapy was completed at least 24 weeks prior to Screening and subject is HCV RNA negative);
  • Has known active bacterial, viral, fungal, or atypical mycobacterial infection, or any major episode of infection that required hospitalization
  • Has received live (including attenuated) vaccination in the 30 days prior to Day 1 or killed vaccine within 14 days prior to Day 1.
  • Is (HIV) positive by antigen/antibody test, human T cell lymphotropic virus (HTLV 1 or 2) positive by antibody test.
  • Has had major surgery (defined as surgery requiring general or regional anesthesia) within 6 weeks prior to Day 1 or is expected to receive surgery during the study.
  • Has a history of organ transplant (e.g., solid, bone marrow) or is expected to receive one during the study.
  • Has any other condition or social situations that would interfere with the subject's study participation, increase the risk associated with study participation or product administration, interfere with the interpretation of study results, or would otherwise make the subject inappropriate for entry into this study in the Investigator's or Sponsor's opinion.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    ABC008 Dose Level 1 Cohort

    0.25 mg / kg ABC008 Subjects receive ABC008 every 8 weeks. Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose.

    Drug: ABC008

  • Experimental
    ABC008 Dose Level 2 Cohort

    0.75 mg / kg ABC008 Subjects receive ABC008 every 8 weeks. Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose.

    Drug: ABC008

  • Experimental
    ABC008 Dose Level 3 Cohort

    1.5 mg / kg ABC008 Subjects receive ABC008 every 8 weeks. Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose.

    Drug: ABC008

  • Experimental
    ABC008 Dose Level 4 Cohort

    3.0 mg / kg ABC008 Subjects receive ABC008 every 8 weeks OR 1.5 mg / kg Subjects receive ABC008 every 4 weeks. Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose.

    Drug: ABC008

  • Experimental
    ABC008 Dose Level 5 Cohort

    3.0 mg / kg ABC008 Subjects receive ABC008 every 4 weeks. Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose.

    Drug: ABC008

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence, nature, and severity of treatment-emergent AEs and SAEs as determined by NCI CTCAE v5.0

    Time frame: Through Study Completion an average of 48 weeks

Secondary outcomes

  1. Change from baseline in safety lab (Hematology)

    Time frame: Through Study Completion an average of 48 weeks

  2. Change from baseline in safety lab (Chemistry)

    Time frame: Through Study Completion an average of 48 weeks

  3. Change from baseline in safety lab (Coagulation)

    Includes the following coagulation labs: INR and aPTT

    Time frame: Through Study Completion an average of 48 weeks

  4. Change from baseline in safety lab (Complement)

    Includes the following complement labs: C3 and CH50

    Time frame: Through Study Completion an average of 48 weeks

  5. Change from baseline in safety lab (Cytokines)

    Time frame: Through Study Completion an average of 48 weeks

  6. Change from baseline in safety lab (CMV Viral Load)

    Time frame: Through Study Completion an average of 48 weeks

  7. Change from baseline in safety lab (EBV Viral Load)

    Time frame: Through Study Completion an average of 48 weeks

  8. Change from baseline in ECG (Rhythm)

    Time frame: Through Study Completion an average of 48 weeks

  9. Change from baseline in ECG (Heart Rate)

    Time frame: Through Study Completion an average of 48 weeks

  10. Change from baseline in ECG parameters

    Includes the following ECG parameters: RR interval, PR interval, QRS interval, QT interval, QT interval corrected by Bazett's formula, and QTcF

    Time frame: Through Study Completion an average of 48 weeks

  11. Change from baseline in vital sign (Systolic and diastolic blood pressure)

    Time frame: Through Study Completion an average of 48 weeks

  12. Change from baseline in vital sign (temperature)

    Time frame: Through Study Completion an average of 48 weeks

  13. Change from baseline in vital sign (respiratory rate)

    Time frame: Through Study Completion an average of 48 weeks

  14. Change from baseline in vital sign (pulse rate)

    Time frame: Through Study Completion an average of 48 weeks

  15. Percentage of subjects demonstrating overall response (defined as total number of subjects with CR or PR) at all time points assessed

    Time frame: Day 1 and throughout the 48 weeks of follow up

  16. Percentage of subjects demonstrating complete response at all time points assessed

    A complete response is defined by normalization of hemoglobin, neutrophil and platelet levels without transfusion

    Time frame: Day 1 and throughout the 48 weeks of follow up

  17. Percentage of subjects demonstrating partial response at all time points assessed

    A partial response is defined by improvement in any of the following criteria but not all: hemoglobin, neutrophil and platelet levels without transfusion

    Time frame: Day 1 and throughout the 48 weeks of follow up

  18. Duration of response at all time points assessed

    Time frame: Day 1 and throughout the 48 weeks of follow up

  19. Overall survival at Week 48

    Time frame: Day 1 and throughout the 48 weeks of follow up

  20. The change from baseline in levels of KLRG1 expressing lymphocytes over time

    Time frame: Day 1 and throughout the 48 weeks of follow up

  21. The change from baseline in levels of T-LGL counts over time

    Time frame: Day 1 and throughout the 48 weeks of follow up

  22. The change from baseline in levels of lymphocyte subsets over time

    Time frame: Day 1 and throughout the 48 weeks of follow up

  23. The maximum serum concentration [CMax] of ABC008

    Time frame: Day 1 and throughout the 48 weeks of follow up

  24. The time to maximum concentration [TMax] of ABC008

    Time frame: Day 1 and throughout the 48 weeks of follow up

  25. The area under the concentration-time curve [AUC] of ABC008

    Time frame: Day 1 and throughout the 48 weeks of follow up

  26. The apparent clearance [CL/F] of ABC008

    Time frame: Day 1 and throughout the 48 weeks of follow up

  27. The apparent volume of distribution [Vd/F] of ABC008

    Time frame: Day 1 and throughout the 48 weeks of follow up

  28. The elimination half-life [t½] of ABC008

    Time frame: Day 1 and throughout the 48 weeks of follow up

07

Study locations

8 sites
  • City of Hope
    Duarte, California 91010, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • The University of Texas M.D. Anderson Cancer Center
    Houston, Texas 77030, United States
  • Huntsman Cancer Institute, University of Utah
    Salt Lake City, Utah 84112, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Aug 2025, 35 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2022
First posted
Sep 8, 2022
StartActual
Sep 28, 2022
Primary completionActual
Aug 28, 2025
CompletionActual
Mar 31, 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05532722
Lead sponsor
Abcuro, Inc.
Responsible party
Sponsor
First posted
Sep 8, 2022
Start date
Sep 28, 2022
Primary completion
Aug 28, 2025
Completion
Mar 31, 2026
Last update
May 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ulviprubart

Start the discussion